Lantheus Holdings (STU:0L8) Research & Development: €155 Mil (TTM As of Mar. 2026)


STU:0L8 Lantheus Holdings Inc STU:0L8
87 GF Score
Price €96.50
GF Value €79.89
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lantheus Holdings Research & Development?

Lantheus Holdings STU:0L8 +1.37% 87 Research & Development is €155 Mil as of Mar. 2026. GuruFocus rates STU:0L8 with a GF Score™ of 87/100 and a GF Value™ of €79.89 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Lantheus Holdings's Research & Development for the three months ended in Mar. 2026 was €34 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €155 Mil.

Lantheus Holdings  (STU:0L8) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Lantheus Holdings Research & Development Related Terms

Lantheus Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Lantheus Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lantheus Holdings Research & Development Chart

Lantheus Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.80 294.23 71.26 160.53 151.42

Lantheus Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.59 39.44 40.92 40.55 34.06
STU:0L8
87GF Score
Lantheus Holdings Inc STU:0L8
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lantheus Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €155 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €155 Mil mean?
Lantheus Holdings (STU:0L8) has a Research & Development of €155 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Lantheus Holdings and its competitors.
Is Lantheus Holdings' Research & Development too high?
Lantheus Holdings' current Research & Development is €155 Mil. Overall, Lantheus Holdings has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' Research & Development compare to LQDA and HIMS?
Lantheus Holdings' Research & Development of €155 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Lantheus Holdings and its competitors. Lantheus Holdings's current Research & Development is €155 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (STU:0L8) is currently considered Modestly Overvalued. The stock's GF Value™ is €79.89, compared to a current price of €96.50 — trading 20.8% above its estimated fair value. The current Research & Development is €155 Mil. Lantheus Holdings' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Lantheus Holdings (STU:0L8), the current Research & Development is €155 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lantheus Holdings (STU:0L8) Overvalued in 2026?

Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued. The current stock price of €96.50 is trading 20.8% above its estimated GF Value™ of €79.89. GuruFocus considers Lantheus Holdings to be Modestly Overvalued.

Key valuation signals for STU:0L8:

  • Research & Development: €155 Mil
  • GF Value™: €79.89 vs. price of €96.50 (20.8% above fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the STU:0L8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lantheus Holdings Business Description

Other Exchanges LNTH:USA1LNTH:Italy
Address 201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
87GF Score

Get the complete analysis for STU:0L8

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€96.50
Price
€79.89
GF Value